A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST

Int J Clin Exp Pathol. 2015 May 1;8(5):5113-20. eCollection 2015.

Abstract

Development of malignant peripheral nerve sheath tumors (MPNSTs) is a stepwise process that involves the alteration of many cell cycle regulators and the double inactivation of the NF1 gene. Inactivation of the TP53 gene and deletion of the CDKN2A/p16 gene are known to play an important role in the process. Herein, we present a 19-year-old man with a familial history of neurofibromatosis type 1, in whom the tumor arose from the intercostal nerve and showed 3 components: a neurofibroma, a low-grade MPNST, and a high-grade MPNST. Loss of p16 expression and homozygous deletion of the CDKN2A/p16 gene were observed in both the low-grade and the high-grade MPNST. In contrast to low-grade MPNSTs, high-grade MPNSTs generally tend to lose expression of p16 and harbor homozygous deletion of the CDKN2A/p16 gene. Loss of p16 expression and homozygous deletion of the CDKN2A/p16 gene in low-grade MPNST in our case might be related to its progression to high-grade MPNST. To the best of our knowledge, this is the first study correlating the p16 expression status and CDKN2A/p16 gene alteration in low-grade MPNSTs.

Keywords: CDKN2A/p16 gene; Malignant peripheral nerve sheath tumor; high grade; homozygous deletion; immunohistochemistry; low grade; neurofibromatosis type 1; p16.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics*
  • Biopsy
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics*
  • Disease Progression
  • Gene Deletion*
  • Genetic Predisposition to Disease
  • Homozygote
  • Humans
  • Immunohistochemistry
  • Male
  • Neoplasm Grading
  • Neurilemmoma / chemistry
  • Neurilemmoma / genetics*
  • Neurilemmoma / pathology
  • Neurilemmoma / therapy
  • Neurofibroma / chemistry
  • Neurofibroma / genetics*
  • Neurofibroma / pathology
  • Neurofibroma / therapy
  • Neurosurgical Procedures
  • Phenotype
  • Radiotherapy, Adjuvant
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Cyclin-Dependent Kinase Inhibitor p16